AMETEK Announces Agreement to Acquire Paragon Medical

AMETEK, Inc. (NYSE: AME) today announced that it has entered into a definitive agreement to acquire Paragon Medical, a leading provider of highly engineered medical components and instruments, from affiliates of American Securities LLC in an all-cash transaction valued at approximately $1.9 billion.

Paragon Medical serves a wide range of specialty applications including orthopedics, minimally invasive surgery, robotic surgery, and drug delivery. Paragon’s product portfolio includes single-use and consumable surgical instruments and implantable components sold to a diverse blue-chip customer base of leading medical device manufacturers.

“We are excited for the opportunity to acquire such an outstanding business,” said David A. Zapico, AMETEK Chairman and Chief Executive Officer. “Paragon meaningfully expands our presence in the MedTech space and provides us access to attractive new market segments with strong growth rates. Its products and capabilities nicely complement AMETEK’s existing medical businesses enabling geographic and customer expansion opportunities.”

Paragon Medical has annual sales of approximately $500 million and is headquartered in Pierceton, Indiana. The transaction is subject to customary closing conditions, including applicable regulatory approvals.

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

he Intracept system, a basivertebral nerve ablation therapy, will be an addition to the Boston Scientific chronic pain portfolio that includes spinal cord stimulation, radiofrequency ablation and an interspinous spacer procedure.
"As Probo Medical has grown, we've seen the value of tailoring our commercial offering to the specific needs of specialists that we serve. Davis Medical provides us with exactly that in the cardiology specialty, with decades of experience and a refined approach to support cardiology practices with the equipment, services and supplies they need to run their practice," said Michael Asmer, CEO of Probo. "Additionally, the Davis Medical team adds significant strength to our footprint in the western US."
“This acquisition will provide a much-needed treatment to patients in need,” said Orlaith Ryan, chief technical officer and co-founder of Shorla Oncology. “It brings a crucial oral treatment to a larger patient population who suffer from cancer and other debilitating illnesses.”
“Time is of the essence during medical emergencies, as we saw in 2022 when EU member states required emergency shipments of Tecovirimat SIGA to treat patients infected with mpox,” said Meridian Medical Technologgies Commercial Head – Injectables & Health Security, Tom Handel. “This joint procurement framework contract, a significant milestone for both Meridian and HERA, reduces the time and effort required to put individual contracts in place with each member state from months to days. There are now multiple paths in Europe for streamlined procurement, allowing member state agencies to get much needed medical countermeasures into the hands of those in need.”
Founded in 1969 and based in Fraser, Michigan, Healthmark Industries is a leading manufacturer, marketer, and distributor of consumable medical devices and supplies used by sterile processing departments in hospitals for cleaning verification and sterile instrument packaging. In its fiscal year ending October 31, 2023, Healthmark expects revenue to increase 15% to $126 million.

By using this website you agree to accept Medical Device News Magazine Privacy Policy